{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "shortName": "BLUEBIRD BIO INC.  DL-,01", "messageBoardId": "finmb_28921", "exchangeTimezoneShortName": "CEST", "market": "dr_market", "gmtOffSetMilliseconds": 7200000, "esgPopulated": false, "exchange": "MUN", "longName": "bluebird bio, Inc.", "regularMarketChangePercent": -3.6327603, "regularMarketPrice": 4.377, "exchangeTimezoneName": "Europe/Berlin", "marketState": "REGULAR", "regularMarketChange": -0.16499996, "regularMarketTime": 1683871317, "regularMarketDayHigh": 4.377, "regularMarketDayRange": "4.377 - 4.377", "regularMarketDayLow": 4.377, "regularMarketVolume": 260, "regularMarketPreviousClose": 4.542, "bid": 3.999, "ask": 4.028, "fullExchangeName": "Munich", "financialCurrency": "USD", "regularMarketOpen": 4.377, "averageDailyVolume3Month": 7, "averageDailyVolume10Day": 34, "fiftyTwoWeekLowChange": 1.7319999, "fiftyTwoWeekLowChangePercent": 0.6548204, "fiftyTwoWeekRange": "2.645 - 7.887", "fiftyTwoWeekHighChange": -3.5100002, "fiftyTwoWeekHighChangePercent": -0.44503617, "fiftyTwoWeekLow": 2.645, "fiftyTwoWeekHigh": 7.887, "earningsTimestamp": 1683630000, "earningsTimestampStart": 1690973940, "earningsTimestampEnd": 1691409600, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -3.51, "sharesOutstanding": 106383000, "bookValue": 2.368, "fiftyDayAverage": 3.86384, "fiftyDayAverageChange": 0.51315975, "fiftyDayAverageChangePercent": 0.13281082, "twoHundredDayAverage": 5.76808, "twoHundredDayAverageChange": -1.3910804, "twoHundredDayAverageChangePercent": -0.2411687, "marketCap": 465638368, "priceToBook": 1.8483952, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1516863600000, "priceHint": 4, "symbol": "BLE.MU"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "455 Grand Union Boulevard", "city": "Somerville", "state": "MA", "zip": "02145", "country": "United States", "phone": "339 499 9300", "website": "https://www.bluebirdbio.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent \u00df-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with \u00df-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.", "fullTimeEmployees": 323, "companyOfficers": [{"maxAge": 1, "name": "Mr. Andrew  Obenshain", "age": 48, "title": "Pres, CEO & Director", "yearBorn": 1974, "fiscalYear": 2022, "totalPay": {"raw": 1041870, "fmt": "1.04M", "longFmt": "1,041,870"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Thomas J. Klima", "age": 50, "title": "Chief Commercial Officer & COO", "yearBorn": 1972, "fiscalYear": 2022, "totalPay": {"raw": 654969, "fmt": "654.97k", "longFmt": "654,969"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Richard A. Colvin M.D., Ph.D.", "age": 56, "title": "Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": {"raw": 696239, "fmt": "696.24k", "longFmt": "696,239"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Christopher  Krawtschuk CPA", "age": 48, "title": "CFO, Principal Accounting Officer & Treasurer", "yearBorn": 1974, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Joseph D. Vittiglio Esq., J.D.", "age": 50, "title": "Chief Legal & Bus. Officer and Sec.", "yearBorn": 1972, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Jess  Rowlands", "title": "Head of Corp. Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Andrea  Walton", "title": "Chief People Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Melissa  Bonner", "title": "Sr. VP of Research", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Kasra  Kasraian", "title": "Sr. VP of Technical Devel. & Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Scott  Shoemaker", "title": "Sr. VP of Quality", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 5, "compensationRisk": 7, "shareHolderRightsRisk": 5, "overallRisk": 6, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}